HRCT Useful In Sclerodermal Lung Disease Treatment PDF Print E-mail
Thursday, 26 November 2009 10:46
In a recent Reuters Health article, it was reported that the serial scanning of the thorax with high-resolution computed tomography (HRCT) is useful for monitoring the response of Sclerodermal lung disease to therapy, according to a further report in the November Chest.

The report focused on 98 patients with sclerodermal-interstitial lung disease who had completed one year of treatment with either cyclophosphamide or placebo in a randomized Scleroderma Lung Study. According to senior author Dr. Donald P. Tashkin, from the University of California, the cyclophosphamide produced significant improvements in pulmonary function and symptoms. Dr. Tashkin, and his colleagues also compared parenchymal abnormalities between baseline and follow-up HRCT scans.

Amongst the 49 patients in the cyclophosphamide arm, 14 had worse fibrosis scores at 12 months and 35 had scores that were not worse. In contrast, among the 49 patients in the placebo group, 26 had worse fibrosis scores at 12 months and 23 had scores that were not worse.

HRCT fibrosis scores correlated with pulmonary function and skin thickness scores, the investigators said, and changes in dyspnea over time showed moderate correlations with changes in fibrosis.

"Our findings provide a rationale for performing follow-up HRCT scans in patients with scleroderma interstitial lung disease undergoing treatment with oral cyclophosphamide or some other potentially active agent as a means of assessing the patient's response to therapy and determining whether additional treatment is needed in patients with HRCT evidence of progressive fibrosis despite their existing therapy," Dr. Tashkin told Reuters Health.

"HRCT scans provide an objective method of assessing changes in both inflammation and fibrosis in the lungs of patients with interstitial lung disease," he added. "They therefore provide a useful complement to measured changes in lung physiology."

For a link to the full and original article, click here.
 
More articles :

» Scleroderma Drug In Development

According to , has partnered with , the health care investment arm of Morgan Keegan and Co. Inc., to jump-start a capital campaign to raise $12 million to $15 million. ArGentis shelved the campaign last year when the economy soured.The money will...

» Actelion Fibrosis Drug Doesn't Meet Key Endpoint

Actelion Ltd today announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of Bosentan in patients suffering from idiopathic pulmonary fibrosis. While there was a consistent trend in favour of Bosentan, the...

» Capillaroscopy, Autoantibody Findings Predict Raynaud's Progression

Abnormal findings on nailfold and the presence of scleroderma-specific autoantibodies in patients presenting with new-onset without overt connective tissue disease are powerful independent predictors of progression to definite .A landmark Canadian...

» The Incidence Of Prostate Cancer Higher In Men With Autoimmune Diseases

Men with autoimmune diseases have a higher incidence of (PCa) than those without those diseases, according to study findings presented at the annual meeting.Using the National Inpatient Sample database, researchers obtained data on 189,290 men...

» Simple Predictor In Scleroderma Related Interstitial Lung Disease

Patients at high risk of deterioration or death from Systemic Sclerosis-related interstitial lung disease can be readily spotted using CT scans, suggest Melbourne researchers.Patients classified as having “extensive” (> 20%) lung disease as...

» Survival in Pulmonary Hypertension Associated With the Scleroderma Spectrum of Diseases

Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. GirgisObjective. Pulmonary hypertension (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be...

Add comment

Do feel free to leave your comments, as they would add value and knowledge to the community. However, please refrain from making any disparaging, uninformed, or unrelated comments. Thanks :)

Security code
Refresh